Skye Bioscience, Inc. SKYE
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Skye Bioscience, Inc. (SKYE) is a healthcare company listed in the US with a market value of about $5M.
Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is value (2/5); the weakest is future growth (0/5).
Key numbers: a P/E of 0.2, a 5-year average ROIC of -121%.
About Skye Bioscience
Skye Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 1 of the last 10 years in our data. Its share count rose by 1686% over three years (dilution for shareholders).
Score: 0.8 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Net income | -$56M | -$27M | -$38M | -$19M | -$9M | -$7M | $1M | -$19M | -$3M | -$3M |
| Free cash flow | -$43M | -$27M | -$14M | -$13M | -$7M | -$6M | — | -$4M | -$3M | -$4M |
| EPS (diluted) | $-1.41 | $-0.73 | $-5.37 | $-8.77 | $-5.00 | $-7.50 | $-12.50 | $-40.00 | $-27.50 | $-42.50 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -226.4% | -34.8% | — | — | -102.9% | -359.5% | -708.2% | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 2 analysts is $16.00, 1368% above the current price; targets range from $16.00 to $16.00; the consensus rating is “Hold”; expected EPS is $-5.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Skye Bioscience’s P/E ratio?
About 0.2, based on the last twelve months of diluted earnings per share.
Does Skye Bioscience pay a dividend?
Not currently.
Is Skye Bioscience a good stock to buy?
We do not give buy or sell advice. Skye Bioscience scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.